There have been mixed performances and varying opinions about the potential of the Bristol-Myers Squibb stock (BMY). The stock has seen roses and thorns alike with some loss in certain periods, encouraging gains during others, and mere survivals amidst market volatility. Analysts across the board have consistently held varying views - from 'Hold' to 'Buy', mirroring the market's unpredictable temperament. Bristol-Myers Squibb has been reported to cut costs with a $1.5billion plan following a quarterly loss which triggered an approximate 10% stock jump. There are anticipations of the company rebounding to record highs. It should be noted the Q2 Earnings exceeded estimates and its continually strong drug sales have raised its outlook. Bristol Myers Squibb has signalled a plan to cut 6% of its workforce amidst some lags in the sales of newer drugs. Its CEO hints at a transition and growth later in the decade. Its Q1 2024 Earnings Call Transcript is also available for investors. The US FDA has also approved their colorectal cancer therapy.
Bristol-Myers Squibb BMY News Analytics from Thu, 14 Dec 2023 08:00:00 GMT to Sun, 11 Aug 2024 10:19:13 GMT - Rating 1 - Innovation 3 - Information 6 - Rumor 3